If the shutdown drags on at FDA, it will put anticipated new treatments in jeopardy
If it drags on, the government shutdown at FDA could jeopardize highly anticipated new drugs from Janssen, Sanofi and Novartis, among other companies.
WASHINGTON — The government shutdown could soon jeopardize highly anticipated new drugs from Janssen, Sanofi and Novartis for depression, diabetes and multiple sclerosis, as well as a host of other potential new therapies, according to a STAT analysis of upcoming regulatory decision dates.
President Trump has warned that the shutdown — already the longest in history — could stretch on for “months or even years.” And though the Food and Drug Administration can retain more than half of its workforce thanks to application fees paid by drug and device makers, Commissioner Scott Gottlieb has
